References
- Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet366, 237–248 (2005).
- Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry2, 104–113 (2003).
- Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am. Fam. Physician62, 2077–2086, 2091–2092 (2000).
- Buitelaar J, Medori R. Treating attention-deficit/hyperactivity disorder beyond symptom control alone in children and adolescents: a review of the potential benefits of long-acting stimulants. Eur. Child Adolesc. Psychiatry19, 325–340 (2010).
- Danckaerts M, Sonuga-Barke EJS, Banaschewski T et al. The quality of life of children with attention deficit/hyperactivity disorder: a systematic review. Eur. Child Adolesc. Psychiatry19, 83–105 (2010).
- Kemner JE, Starr HL, Ciccone PE, Hooper-Wood CG, Crockett RS. Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: a multicenter, randomized prospective study. Adv. Ther.22, 498–512 (2005).
- Newcorn JH, Kratochvil CJ, Allen AJ et al. Atomoxetine/methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am. J. Psychiatry165, 721–730 (2008).
- Conners CK. Rating scales in attention-deficit/hyperactivity disorder: use in assessment and treatment monitoring. J. Clin. Psychiatry59(Suppl. 7), 24–30 (1998).
- Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. Pediatr. Clin. North Am.46, 857–870 (1999).
- Conners CK, Sitarenios G, Parker JD, Epstein JN. The revised Conners’ parent rating scale (CPRS-R): factor structure, reliability, and criterion validity. J. Abnorm. Child Psychol.26, 257–268 (1998).
- Mattejat F, Remschmidt H. [Assessing the quality of life of children and adolescents with psychiatric disorders – an overview]. Z. Kinder Jugendpsychiatr. Psychother.26, 183–196 (1998).
- Mattejat F, Jungmann J, Meusers M et al. [The inventory of life quality in children and adolescents ILC – a pilot study]. Z. Kinder Jugendpsychiatr. Psychother.26, 174–182 (1998).
- Mattejat F, Simon B, König U et al. Lebensqualität bei psychisch kranken Kindern und Jugendlichen. Z. Kinder Jugendpsychiatr. Psychother.31, 293–303 (2003).
- Jozefiak T, Larsson B, Wichstrøm L, Mattejat F, Ravens-Sieberer U. Quality of Life as reported by school children and their parents: a cross-sectional survey. Health Qual. Life Outcomes6, 34–45 (2008).
- Shaffer D, Gould MS, Brasic J et al. A children’s global assessment scale (CGAS). Arch. Gen. Psychiatry40, 1228–1231 (1983).
- Michelson D, Allen AJ, Busner J et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am. J. Psychiatry159, 1896–1901 (2002).
- Hammerness P, Georgiopoulos A, Doyle RL et al. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J. Child Adolesc. Psychopharmacol.19, 493–499 (2009).
- Wilens TE, Hammerness P, Utzinger L et al. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J. Child Adolesc. Psychopharmacol.19, 485–492 (2009).
- Kim HW, Yoon IY, Cho SC et al. The effect of OROS methylphenidate on the sleep of children with attention-deficit/hyperactivity disorder. Int. Clin. Psychopharmacol.25, 107–115 (2010).
- Swanson J, Gupta S, Lam A et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch. Gen. Psychiatry60, 204–211 (2003).